ES2124701T3 - Composiciones de vacunas. - Google Patents

Composiciones de vacunas.

Info

Publication number
ES2124701T3
ES2124701T3 ES91908598T ES91908598T ES2124701T3 ES 2124701 T3 ES2124701 T3 ES 2124701T3 ES 91908598 T ES91908598 T ES 91908598T ES 91908598 T ES91908598 T ES 91908598T ES 2124701 T3 ES2124701 T3 ES 2124701T3
Authority
ES
Spain
Prior art keywords
vaccine compositions
compositions
immuno
activating
additive
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES91908598T
Other languages
English (en)
Inventor
Christopher L Penny
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
North American Vaccine Inc
Original Assignee
North American Vaccine Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by North American Vaccine Inc filed Critical North American Vaccine Inc
Application granted granted Critical
Publication of ES2124701T3 publication Critical patent/ES2124701T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Oscillators With Electromechanical Resonators (AREA)
  • Diaphragms For Electromechanical Transducers (AREA)

Abstract

COMPOSICIONES MEJORADAS PARA UNA VACUNA QUE CONTIENEN UN COMPUESTO DE ALKILO DE CADENA LARGA COMO INMUNOADITIVO JUNTO CON UN POLIPEPTIDO INMUNOGENICO HOMOGENEO. LAS COMPOSICIONES DE LA INVENCION SON UTILES PARA ACTIVAR EL SISTEMA INMUNE PARA CONFERIRLE INMUNIDAD A UN HUESPED CONTRA EN INMUNOGEN DE UNA MANERA PROFILACTICA.
ES91908598T 1990-05-07 1991-05-01 Composiciones de vacunas. Expired - Lifetime ES2124701T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US51846090A 1990-05-07 1990-05-07

Publications (1)

Publication Number Publication Date
ES2124701T3 true ES2124701T3 (es) 1999-02-16

Family

ID=24064028

Family Applications (1)

Application Number Title Priority Date Filing Date
ES91908598T Expired - Lifetime ES2124701T3 (es) 1990-05-07 1991-05-01 Composiciones de vacunas.

Country Status (22)

Country Link
EP (1) EP0597838B1 (es)
JP (1) JPH05506234A (es)
CN (1) CN1056816A (es)
AT (1) ATE173936T1 (es)
AU (1) AU7777991A (es)
CA (1) CA2082425A1 (es)
CS (1) CS131891A3 (es)
DE (1) DE69130576T2 (es)
DK (1) DK0597838T3 (es)
ES (1) ES2124701T3 (es)
FI (1) FI925032A0 (es)
HR (1) HRP930658A2 (es)
HU (1) HUT65493A (es)
IE (1) IE911527A1 (es)
IL (1) IL97985A0 (es)
MX (1) MX172210B (es)
NO (1) NO924271L (es)
NZ (1) NZ238042A (es)
TW (1) TW221676B (es)
WO (1) WO1991016926A1 (es)
YU (1) YU79691A (es)
ZA (1) ZA913214B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA22842A1 (fr) * 1992-03-27 1993-10-01 Smithkline Beecham Biolog Procede de preparation de compositions de vaccin.
US6620414B2 (en) 1992-03-27 2003-09-16 Smithkline Beecham Biologicals (S.A.) Hepatitis vaccines containing 3-0-deacylated monophoshoryl lipid A
AU3541495A (en) * 1994-09-01 1996-03-22 Wisconsin Alumni Research Foundation Therapeutic remodeling in aids
FR2726471B1 (fr) * 1994-11-07 1997-01-31 Pf Medicament Procede pour ameliorer l'immunogenicite d'un compose immunogene ou d'un haptene et application a la preparation de vaccins
US6027731A (en) * 1998-11-17 2000-02-22 Wisconsin Alumni Research Foundation Pertussis toxin induced lymphocytosis
EP1980617A1 (en) 1998-12-31 2008-10-15 Novartis Vaccines and Diagnostics, Inc. Improved expression of HIV polypeptides and production of virus-like particles
WO2000039304A2 (en) 1998-12-31 2000-07-06 Chiron Corporation Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
AU2596600A (en) 1998-12-31 2000-07-31 Chiron Corporation Modified hiv env polypeptides
CA2452015C (en) 2001-07-05 2012-07-03 Chiron Corporation Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
US20030170614A1 (en) 2001-08-31 2003-09-11 Megede Jan Zur Polynucleotides encoding antigenic HIV type B polypeptides, polypeptides and uses thereof
WO2004032824A2 (en) * 2002-10-10 2004-04-22 Yeda Research And Development Co. Ltd. Basic esters of fatty alcohols and their use as anti-inflammatory or immunomodulatory agents

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1138773A (en) * 1979-04-18 1983-01-04 Connaught Laboratories Limited Synthetic adjuvants for stimulation of antigenic responses
US4639371A (en) * 1984-10-02 1987-01-27 New York Blood Center, Inc. Hepatitis B antigenic compositions and vaccines against hepatitis B derived therefrom
GB8807860D0 (en) * 1988-04-05 1988-05-05 Connaught Lab Pertussis vaccine
NZ230424A (en) * 1988-08-25 1992-05-26 Liposome Co Inc Liposomal composition comprising an externally disposed antigen

Also Published As

Publication number Publication date
WO1991016926A1 (en) 1991-11-14
NZ238042A (en) 1993-12-23
CS131891A3 (en) 1992-02-19
HU9203480D0 (en) 1993-01-28
NO924271L (no) 1993-01-07
FI925032L (fi) 1992-11-06
DE69130576D1 (de) 1999-01-14
NO924271D0 (no) 1992-11-06
EP0597838B1 (en) 1998-12-02
HUT65493A (en) 1994-06-28
ATE173936T1 (de) 1998-12-15
CN1056816A (zh) 1991-12-11
ZA913214B (en) 1992-09-30
FI925032A7 (fi) 1992-11-06
EP0597838A1 (en) 1994-05-25
DK0597838T3 (da) 1999-08-16
DE69130576T2 (de) 1999-07-29
HRP930658A2 (en) 1997-12-31
YU79691A (sh) 1994-06-10
AU7777991A (en) 1991-11-27
IL97985A0 (en) 1992-06-21
CA2082425A1 (en) 1991-11-08
TW221676B (es) 1994-03-11
JPH05506234A (ja) 1993-09-16
IE911527A1 (en) 1991-11-20
MX172210B (es) 1993-12-07
FI925032A0 (fi) 1992-11-06

Similar Documents

Publication Publication Date Title
ES2084827T3 (es) Composiciones de vacuna mejoradas.
ES2154263T3 (es) Vacuna a base de conjugados de o-polisacarido-proteina de escherichia coli.
MX9306841A (es) Vacuna a base de ureasa contra la infeccion por helicobacter en mamiferos.
ATE272410T1 (de) Adjuvanszusammensetzungen zur erhöhung der immunantwort auf polynukleotid-basierende impfstoffe
DE3852761D1 (de) Saponin-hilfsmittel.
BRPI0007936B8 (pt) composto, formulação adjuvante imunológica, e formulação de vacina.
ES2142848T3 (es) E-coli p-fimbrina como sistema portador inmunogenico contra gnrh.
DK0597838T3 (da) Vaccinesammensætninger
ES2054732T3 (es) Un procedimiento para preparar un derivado peptidico.
HUP9701586A2 (hu) Javított inaktivált vakcinák
ES343736A1 (es) Procedimiento para preparar una composicion aromatica.
ES2043901T3 (es) Adyuvante para la terapia inmunologica del cancer.
PL341541A1 (en) Isolated strains of staphyloccoccus aureus and vaccines prepared of them
ATE16348T1 (de) Ozon-inaktivierte keime als vakzine.
ES2076399T3 (es) Estimulacion inmunologica del efecto somatogenico de la somatotropina con un anticuerpo.
ES372576A1 (es) Procedimiento para la obtencion de derivados del acido ace-tico bis-(fenoxisustituidos).
RU93005000A (ru) Композиция вакцин, способ ее получения, способ исключения иммунной реакции
GB1109179A (en) Improvements relating to typhoid and paratyphoid vaccines
RU92016460A (ru) Вакцинная композиция, способ индукции иммунной реакции
GB1095666A (en) A novel 9ª‰, 10ª‡-steroid derivative
MX9704824A (es) Adyuvantes para vacunas.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 597838

Country of ref document: ES